Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well medroxyprogesterone works in treating patients with
endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not
including the cervix). Hormone therapy using medroxyprogesterone may be effective in treating
endometrioid cancer.